ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$28.19

Market cap

$3.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.24

Enterprise value

$3.49B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The quick ratio has soared by 132% from the previous quarter and by 27% YoY
The equity has grown by 8% YoY
ARWR's EPS has plunged by 199% YoY and by 54% from the previous quarter
The company's revenue has shrunk by 87% YoY and by 80% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
124.2M
Market cap
$3.5B
Enterprise value
$3.49B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.22
Price to sales (P/S)
97.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
98.45
Earnings
Revenue
$35.47M
EBIT
-$448.3M
EBITDA
-$432.38M
Free cash flow
-$470.16M
Per share
EPS
-$4.24
Free cash flow per share
-$3.81
Book value per share
$3.9
Revenue per share
$0.29
TBVPS
$7.67
Balance sheet
Total assets
$955.15M
Total liabilities
$459.75M
Debt
$118.92M
Equity
$483.79M
Working capital
$476.48M
Liquidity
Debt to equity
0.25
Current ratio
8.31
Quick ratio
8.03
Net debt/EBITDA
0.02
Margins
EBITDA margin
-1,218.9%
Gross margin
100%
Net margin
-1,327.2%
Operating margin
-1,335.6%
Efficiency
Return on assets
-59.9%
Return on equity
-147.1%
Return on invested capital
-63.3%
Return on capital employed
-50.4%
Return on sales
-1,263.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-2.59%
1 week
-0.39%
1 month
7.35%
1 year
-19.69%
YTD
-7.88%
QTD
8.46%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$35.47M
Gross profit
$35.47M
Operating income
-$473.77M
Net income
-$470.79M
Gross margin
100%
Net margin
-1,327.2%
The company's revenue has shrunk by 87% YoY and by 80% QoQ
The gross profit has shrunk by 87% YoY and by 80% QoQ
The net income has dropped by 59% since the previous quarter
The operating income has dropped by 58% since the previous quarter

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
ARWR P/E details
P/E
N/A
P/B
7.22
P/S
97.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
98.45
ARWR's EPS has plunged by 199% YoY and by 54% from the previous quarter
The price to book (P/B) is 39% lower than the last 4 quarters average of 12.2 and 38% lower than the 5-year quarterly average of 12.0
The equity has grown by 8% YoY
The price to sales (P/S) is 179% more than the last 4 quarters average of 36.1 and 163% more than the 5-year quarterly average of 38.3
The company's revenue has shrunk by 87% YoY and by 80% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 180% YoY and by 54% QoQ
The company's return on assets has shrunk by 55% QoQ
The company's return on equity has shrunk by 54% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 108% higher than its total liabilities
The quick ratio has soared by 132% from the previous quarter and by 27% YoY
The company's current ratio has surged by 123% QoQ and by 26% YoY
Arrowhead Pharmaceuticals's debt is 75% lower than its equity
The debt to equity has plunged by 66% from the previous quarter but it has grown by 32% YoY
Arrowhead Pharmaceuticals's debt has increased by 44% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.